Are you over 18 and want to see adult content?
More Annotations
A complete backup of mediamilitia.com
Are you over 18 and want to see adult content?
A complete backup of duartegarcia.com.br
Are you over 18 and want to see adult content?
A complete backup of concept-s-design.com
Are you over 18 and want to see adult content?
A complete backup of sidmouthfolkfestival.co.uk
Are you over 18 and want to see adult content?
A complete backup of allfreejewelrymaking.com
Are you over 18 and want to see adult content?
A complete backup of aboavetusarsnova.fi
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://constellationsofwords.com
Are you over 18 and want to see adult content?
A complete backup of https://theblackfriday.com
Are you over 18 and want to see adult content?
A complete backup of https://natronaschools.org
Are you over 18 and want to see adult content?
A complete backup of https://narine-forte.ru
Are you over 18 and want to see adult content?
A complete backup of https://embarcaderocenter.com
Are you over 18 and want to see adult content?
A complete backup of https://doubleblindmag.com
Are you over 18 and want to see adult content?
A complete backup of https://slinko.com.ua
Are you over 18 and want to see adult content?
A complete backup of https://pacojet.com
Are you over 18 and want to see adult content?
A complete backup of https://alqurumresort.com
Are you over 18 and want to see adult content?
A complete backup of https://tescobanking.info
Are you over 18 and want to see adult content?
A complete backup of https://greenfleetmagazine.com
Are you over 18 and want to see adult content?
A complete backup of https://witchery.com.au
Are you over 18 and want to see adult content?
Text
belonging.
WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications. PIPELINE – HUMACYTE VASCULAR TRAUMA: Traumatic events (home or vehicle accidents, falls, or violent crimes) can cause life-threatening injuries to blood vessels. Surgeons treating these injuries need to urgently repair or replace the damaged blood vessels to help restore circulation quicklyand save limbs.
IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
WHO WE ARE - HUMACYTE Our ongoing commitment. Produce Humacyte’s life-sustaining, human, bioengineered HAV designed to become the patient’s own and integrate naturally for patients who need a better clinical alternative for vascular access. What matters to us We are committed to becoming the leader in novel, human acellular matrix products for vascular and non-vascular applications. These products are CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54.JOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies HOME - HUMACYTEWHAT WE DOWHO WE AREIN THE NEWSPUBLICATIONS & TRIALSJOIN OUR TEAMCONTACT US At Humacyte, we strive to be a part of the change we need to see in the world. This means creating a culture with a strong sense ofbelonging.
WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications. PIPELINE – HUMACYTE VASCULAR TRAUMA: Traumatic events (home or vehicle accidents, falls, or violent crimes) can cause life-threatening injuries to blood vessels. Surgeons treating these injuries need to urgently repair or replace the damaged blood vessels to help restore circulation quicklyand save limbs.
IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
WHO WE ARE - HUMACYTE Our ongoing commitment. Produce Humacyte’s life-sustaining, human, bioengineered HAV designed to become the patient’s own and integrate naturally for patients who need a better clinical alternative for vascular access. What matters to us We are committed to becoming the leader in novel, human acellular matrix products for vascular and non-vascular applications. These products are CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54.JOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies TECHNOLOGY – HUMACYTE Our first product candidate, the HAV, is made by seeding vascular cells from a qualified cell bank onto a polymer mesh in a bioreactor bag. Over weeks, the cells grow and create new tissue, forming a tube-shaped vessel structure. PIPELINE – HUMACYTE VASCULAR TRAUMA: Traumatic events (home or vehicle accidents, falls, or violent crimes) can cause life-threatening injuries to blood vessels. Surgeons treating these injuries need to urgently repair or replace the damaged blood vessels to help restore circulation quicklyand save limbs.
PUBLICATIONS
Main Menu. Company; Technology; Pipeline; Investors; About Menu Toggle. Contact; Careers; PUBLICATIONS HUMACYTE TO PRESENT LONG-TERM FOLLOW-UP DATA FROM PHASE 2 DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted HUMACYTE APPOINTS FOUNDER LAURA NIKLASON MD, PHD AS Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer. Jeffrey Lawson MD, PhD has been appointed the newly established role of Chief Surgical Officer and Vice Chairman. Dr. Laura Niklason, a world leader in tissueengineering and
HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT VIRTUALLY AT DURHAM, N.C. (January 12, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, including the Company’s late-stage HUMACYTE TO PRESENT AT OPPENHEIMER 31ST ANNUAL HEALTHCARE DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT. On CONFLICT OF INTEREST Conflict of Interest FINANCIAL CONFLICT OF INTEREST RELATED TO RESEARCH Policy Statement Humacyte, Inc. is committed to overseeing the conduct of research in a manner that ensures the integrity of the research process and maintains the public trust and that of sponsors in the integrity and credibility of its staff and its research programs. This Conflict of Interest Read More » HUMACYTE COMMENCES PHASE II VASCULAR TRAUMA TRIAL Study evaluates HUMACYL for use in patients undergoing vascular replacement or reconstructive vascular surgery RESEARCH TRIANGLE PARK, N.C. – October 25, 2018. Humacyte, an innovator in biotechnology and regenerative medicine, announced the initiation of a U.S. Phase II vascular trauma clinical trial of HUMACYL®, its investigational human acellular vessel (HAV), for vascular CLINICAL IMPLEMENTATION OF THE HUMACYTE HUMAN ACELLULAR the surgicalwound created to remove thevein is not insignificant and itself becomes infected in 5% to 10% of cases.6–8 Whensaphenous vein is not available, synthetic grafts in- HOME - HUMACYTEWHAT WE DOWHO WE AREIN THE NEWSPUBLICATIONS & TRIALSJOIN OUR TEAMCONTACT US The Power of Vascular Innovation. Humacyte’s Human Acellular Vessel (HAV): An investigational product designed to fulfill the potential of regenerative medicine. WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications.IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
PUBLICATIONS & TRIALS Humacyte Clinical Trials and Publications Clinical Trials VASCULAR ACCESS VASCULAR TRAUMA PERIPHERAL ARTERIAL DISEASE (PAD) FUTURE APPLICATIONS PUBLICATIONS HUMANITY V006 HAV-ACCESS V007 US PAD TRIAL Publications “Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis” Kidney 360 2020 Click HereJOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54. HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies HUMACYTE APPOINTS DOUG BLANKENSHIP AS CHIEF FINANCIAL Life Science Finance Executive Strengthens Management Team Humacyte, an innovator in biotechnology and regenerative medicine, announced today the appointment of Douglas L. Blankenship as Chief Financial Officer, effective Monday, October 8, 2018. Mr. Blankenship is a highly accomplished financial professional with executive-level experience in financing, finance and accounting, technical HOME - HUMACYTEWHAT WE DOWHO WE AREIN THE NEWSPUBLICATIONS & TRIALSJOIN OUR TEAMCONTACT US The Power of Vascular Innovation. Humacyte’s Human Acellular Vessel (HAV): An investigational product designed to fulfill the potential of regenerative medicine. WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications.IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
PUBLICATIONS & TRIALS Humacyte Clinical Trials and Publications Clinical Trials VASCULAR ACCESS VASCULAR TRAUMA PERIPHERAL ARTERIAL DISEASE (PAD) FUTURE APPLICATIONS PUBLICATIONS HUMANITY V006 HAV-ACCESS V007 US PAD TRIAL Publications “Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis” Kidney 360 2020 Click HereJOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54. HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies HUMACYTE APPOINTS DOUG BLANKENSHIP AS CHIEF FINANCIAL Life Science Finance Executive Strengthens Management Team Humacyte, an innovator in biotechnology and regenerative medicine, announced today the appointment of Douglas L. Blankenship as Chief Financial Officer, effective Monday, October 8, 2018. Mr. Blankenship is a highly accomplished financial professional with executive-level experience in financing, finance and accounting, technical TECHNOLOGY – HUMACYTE Our first product candidate, the HAV, is made by seeding vascular cells from a qualified cell bank onto a polymer mesh in a bioreactor bag. Over weeks, the cells grow and create new tissue, forming a tube-shaped vessel structure. PIPELINE – HUMACYTE VASCULAR TRAUMA: Traumatic events (home or vehicle accidents, falls, or violent crimes) can cause life-threatening injuries to blood vessels. Surgeons treating these injuries need to urgently repair or replace the damaged blood vessels to help restore circulation quicklyand save limbs.
PUBLICATIONS & TRIALS Humacyte Clinical Trials and Publications Clinical Trials VASCULAR ACCESS VASCULAR TRAUMA PERIPHERAL ARTERIAL DISEASE (PAD) FUTURE APPLICATIONS PUBLICATIONS HUMANITY V006 HAV-ACCESS V007 US PAD TRIAL Publications “Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis” Kidney 360 2020 Click HerePUBLICATIONS
Main Menu. Company; Technology; Pipeline; Investors; About Menu Toggle. Contact; Careers; PUBLICATIONSJOIN OUR TEAM
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. Humacyte is aware that some job seekers are receiving fake employment offers and requests for personal and banking information from individuals or organizations posing as Humacyte. If you receive an offer that you believe is a scam, please check the email address Join Our Team Read More » HUMACYTE APPOINTS FOUNDER LAURA NIKLASON MD, PHD AS Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer. Jeffrey Lawson MD, PhD has been appointed the newly established role of Chief Surgical Officer and Vice Chairman. Dr. Laura Niklason, a world leader in tissueengineering and
HUMACYTE TO PRESENT LONG-TERM FOLLOW-UP DATA FROM PHASE 2 DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted HUMACYTE TO PRESENT AT OPPENHEIMER 31ST ANNUAL HEALTHCARE DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT. On HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT VIRTUALLY AT DURHAM, N.C. (January 12, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, including the Company’s late-stage EXPANDED ACCESS POLICY Expanded Access Policy Humacyte is a privately held biotechnology company committed to developing and providing innovative and transformative tissue-engineered products to address significant unmet medical needs and significantly improve the quality of life for patients who require vascular surgery. Our initial product is being developed for patients with End Stage Renal Disease who require HOME - HUMACYTEWHAT WE DOWHO WE AREIN THE NEWSPUBLICATIONS & TRIALSJOIN OUR TEAMCONTACT US The Power of Vascular Innovation. Humacyte’s Human Acellular Vessel (HAV): An investigational product designed to fulfill the potential of regenerative medicine. WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications.IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
PUBLICATIONS & TRIALS Humacyte Clinical Trials and Publications Clinical Trials VASCULAR ACCESS VASCULAR TRAUMA PERIPHERAL ARTERIAL DISEASE (PAD) FUTURE APPLICATIONS PUBLICATIONS HUMANITY V006 HAV-ACCESS V007 US PAD TRIAL Publications “Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis” Kidney 360 2020 Click Here CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54.JOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies FRESENIUS MEDICAL CARE AND HUMACYTE ANNOUNCE STRATEGIC BOSTON, June 11, 2018 – PRNewswire— Fresenius Medical Care, the world’s largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte’s investigational human acellular HOME - HUMACYTEWHAT WE DOWHO WE AREIN THE NEWSPUBLICATIONS & TRIALSJOIN OUR TEAMCONTACT US The Power of Vascular Innovation. Humacyte’s Human Acellular Vessel (HAV): An investigational product designed to fulfill the potential of regenerative medicine. WHO WE ARE - HUMACYTE Humacyte’s state-of-the–art facilities reflect a continuing commitment to the quality of our products. Our new state-of-the–art, commercial scale cGMP manufacturing facility is located at 2525 Highway 54 in Durham, NC. The new facility is also home to our Research & Development, Process Development, and Quality Controllaboratories, along
WHAT WE DO - HUMACYTE Humacyte is pioneering the development and manufacture of off-the-shelf, universally available, immediately implantable, bioengineered human tissue. Our Human Acellular Vessel (HAV) is being explored as an innovative, regenerative vascular prosthesis to support repair, reconstruction, and replacement of blood vessels across multiple indications.IN THE NEWS
In The Spotlight From media giants to exclusive industry publications, Humacyte stays in the news. PRESS RELEASES INDUSTRY HIGHLIGHTS PRESS RELEASES INDUSTRY HIGHLIGHTS EVENTS Press ReleasesNews Coverage Laura Niklason to Speak at Milken Institute Future of Health Summit December 9, 2020 Read More Humacyte Appoints Founder Laura Niklason MD, PhD asPresident and
HUMACYTE, A TRANSFORMATIVE BIOTECHNOLOGY PLATFORM COMPANYSEE MORE ONHUMACYTE.COM
PUBLICATIONS & TRIALS Humacyte Clinical Trials and Publications Clinical Trials VASCULAR ACCESS VASCULAR TRAUMA PERIPHERAL ARTERIAL DISEASE (PAD) FUTURE APPLICATIONS PUBLICATIONS HUMANITY V006 HAV-ACCESS V007 US PAD TRIAL Publications “Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis” Kidney 360 2020 Click Here CONTACT US - HUMACYTE Humacyte2525 E NC Highway 54Durham, NC 27713. For all US Postal Mail. please use: Humacyte. 2525 E NC Highway 54.JOIN OUR TEAM-OLD
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. We currently have 10 positions available. Select your area of interest to see available positions.Check back frequently for openings. If you do not see your area of interest above, we are not actively recruiting for that department. Associate Director, Supply Chain Operations Join Our Team-old Read HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies FRESENIUS MEDICAL CARE AND HUMACYTE ANNOUNCE STRATEGIC BOSTON, June 11, 2018 – PRNewswire— Fresenius Medical Care, the world’s largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte’s investigational human acellular TECHNOLOGY – HUMACYTE Our first product candidate, the HAV, is made by seeding vascular cells from a qualified cell bank onto a polymer mesh in a bioreactor bag. Over weeks, the cells grow and create new tissue, forming a tube-shaped vessel structure. PIPELINE – HUMACYTE VASCULAR TRAUMA: Traumatic events (home or vehicle accidents, falls, or violent crimes) can cause life-threatening injuries to blood vessels. Surgeons treating these injuries need to urgently repair or replace the damaged blood vessels to help restore circulation quicklyand save limbs.
WHO WE ARE - HUMACYTE Our ongoing commitment. Produce Humacyte’s life-sustaining, human, bioengineered HAV designed to become the patient’s own and integrate naturally for patients who need a better clinical alternative for vascular access. What matters to us We are committed to becoming the leader in novel, human acellular matrix products for vascular and non-vascular applications. These products areCANNULATION
Cannulation Resources. Humacyte Cannulation Reference Card – ClickHere for PDF.
PUBLICATIONS
Main Menu. Company; Technology; Pipeline; Investors; About Menu Toggle. Contact; Careers; PUBLICATIONSJOIN OUR TEAM
Join our team Cutting edge technology. World-class team. Changing the future of healthcare. Humacyte is aware that some job seekers are receiving fake employment offers and requests for personal and banking information from individuals or organizations posing as Humacyte. If you receive an offer that you believe is a scam, please check the email address Join Our Team Read More » HUMACYTE APPOINTS FOUNDER LAURA NIKLASON MD, PHD AS Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer. Jeffrey Lawson MD, PhD has been appointed the newly established role of Chief Surgical Officer and Vice Chairman. Dr. Laura Niklason, a world leader in tissueengineering and
HUMACYTE CEO DR. LAURA NIKLASON TO PRESENT AT J.P. MORGAN DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39 th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, CONFLICT OF INTEREST Conflict of Interest FINANCIAL CONFLICT OF INTEREST RELATED TO RESEARCH Policy Statement Humacyte, Inc. is committed to overseeing the conduct of research in a manner that ensures the integrity of the research process and maintains the public trust and that of sponsors in the integrity and credibility of its staff and its research programs. This Conflict of Interest Read More » EXPANDED ACCESS POLICY Expanded Access Policy Humacyte is a privately held biotechnology company committed to developing and providing innovative and transformative tissue-engineered products to address significant unmet medical needs and significantly improve the quality of life for patients who require vascular surgery. Our initial product is being developed for patients with End Stage Renal Disease who requireTop
Toggle navigation
* What We Do
* Our Technology
* How It Works
* Benefits Of HAVs
* How HAVs Are Used
* Who We Are
* About Humacyte
* Our Milestones
* Our Team
* Our Facilities
* Our Partners
* In The News
* Press Releases
* Industry Highlights* Events
* Publications & Trials* Publications
* Humanity V006
* HAV-Access V007
* US PAD Trial
* Join Our Team
* Contact Us
* What We Do
* Who We Are
* In The News
* Publications & Trials* Join Our Team
* Contact Us
THE POWER OF
VASCULAR INNOVATION. Imagine a readily available, “off the shelf ” bioengineered human acellular vessel (HAV) that could replace a patient's own blood vessel or create new vascularaccess
for patients who require dialysis, without requiring cells or tissuefrom the patient.
Humacyte is making that happen.What We Do
GROUNDBREAKING
TECHNOLOGY
Our unique process, paired with innovation and continued improvement and evolution, puts us at the forefront. Investigational HAVsWho We Are
MAKING A
MEANINGFUL
IMPACT ON
PATIENT CARE.
About Humacyte
In the News
Surgeons Perform First Bioengineered Blood Vessel Transplant inMilitary Patient
Entrepreneurial Journey First Penn Scholarship Recipient off to Yale Oh, the Places Grads Go Surgeons Perform First Bioengineered Blood Vessel Transplant inMilitary Patient
Entrepreneurial Journey First Penn Scholarship Recipient off to Yale Oh, the Places Grads Go Surgeons Perform First Bioengineered Blood Vessel Transplant inMilitary Patient
* 1
* 2
* 3
* 4
Get more news and updatesWhat We Do
WHY HUMAN ACELLULAR VESSELS (HAV)? From lower costs to fewer operations, HAVs may offer criticalbenefits.
Explore the benefitsContact Us
WE'D LOVE TO
HEAR FROM YOU.
Please select an optionLearning more, as a professionalLearning more, as a patientInvestingOtherWho We Are
OUR PATH
TO SUCCESS.
With each year, we’ve moved closer to lifesaving treatments.Our milestones
Join Our Team
JOIN OUR TEAM
AND MAKE
A DIFFERENCE.
Career opportunities╳
Your browser does not support the video tag.* What We Do
* Who We Are
* In The News
* Publications & Trials* Join Our Team
* Contact Us
2020 Humacyte, Inc. All Rights Reserved.* Privacy Policy
* Expanded Access Policy * Conflict of Interest* Contact
* Sitemap
* © 2020 Humacyte, Inc. All Rights Reserved.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0